These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 11207170)

  • 1. Idiopathic thrombocytopenic purpura and MMR vaccine.
    Miller E; Waight P; Farrington CP; Andrews N; Stowe J; Taylor B
    Arch Dis Child; 2001 Mar; 84(3):227-9. PubMed ID: 11207170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines.
    Farrington P; Pugh S; Colville A; Flower A; Nash J; Morgan-Capner P; Rush M; Miller E
    Lancet; 1995 Mar; 345(8949):567-9. PubMed ID: 7619183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MMR vaccine and idiopathic thrombocytopaenic purpura.
    Black C; Kaye JA; Jick H
    Br J Clin Pharmacol; 2003 Jan; 55(1):107-11. PubMed ID: 12534647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine administration and the development of immune thrombocytopenic purpura in children.
    Cecinati V; Principi N; Brescia L; Giordano P; Esposito S
    Hum Vaccin Immunother; 2013 May; 9(5):1158-62. PubMed ID: 23324619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management.
    Mantadakis E; Farmaki E; Buchanan GR
    J Pediatr; 2010 Apr; 156(4):623-8. PubMed ID: 20097358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is MMR immunisation safe in chronic Idiopathic thrombocytopenic purpura?
    Bibby AC; Farrell A; Cummins M; Erlewyn-Lajeunesse M
    Arch Dis Child; 2008 Apr; 93(4):354-5. PubMed ID: 18356391
    [No Abstract]   [Full Text] [Related]  

  • 7. Vaccination associated thrombocytopenic purpura in children.
    Rajantie J; Zeller B; Treutiger I; Rosthöj S;
    Vaccine; 2007 Feb; 25(10):1838-40. PubMed ID: 17126957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idiopathic thrombocytopenic purpura and the second dose of MMR.
    Stowe J; Kafatos G; Andrews N; Miller E
    Arch Dis Child; 2008 Feb; 93(2):182-3. PubMed ID: 17962371
    [No Abstract]   [Full Text] [Related]  

  • 9. Measles-mumps-rubella vaccination induced thrombocytopenia: a case report and review of the literature.
    Owatanapanich S; Wanlapakorn N; Tangsiri R; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2014 Sep; 45(5):1053-7. PubMed ID: 25417506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents.
    O'Leary ST; Glanz JM; McClure DL; Akhtar A; Daley MF; Nakasato C; Baxter R; Davis RL; Izurieta HS; Lieu TA; Ball R
    Pediatrics; 2012 Feb; 129(2):248-55. PubMed ID: 22232308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy.
    Bertuola F; Morando C; Menniti-Ippolito F; Da Cas R; Capuano A; Perilongo G; Da Dalt L
    Drug Saf; 2010 Jan; 33(1):65-72. PubMed ID: 20000868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines for measles, mumps and rubella in children.
    Demicheli V; Jefferson T; Rivetti A; Price D
    Cochrane Database Syst Rev; 2005 Oct; (4):CD004407. PubMed ID: 16235361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin.
    Berry AA; Abu-Elyazeed R; Diaz-Perez C; Mufson MA; Harrison CJ; Leonardi M; Twiggs JD; Peltier C; Grogg S; Carbayo A; Shapiro S; Povey M; Baccarini C; Innis BL; Henry O
    Hum Vaccin Immunother; 2017 Jul; 13(7):1516-1522. PubMed ID: 28481690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.
    France EK; Glanz J; Xu S; Hambidge S; Yamasaki K; Black SB; Marcy M; Mullooly JP; Jackson LA; Nordin J; Belongia EA; Hohman K; Chen RT; Davis R;
    Pediatrics; 2008 Mar; 121(3):e687-92. PubMed ID: 18310189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute idiopathic thrombocytopenic purpura following combined vaccination against measles, mumps, and rubella.
    Chang SK; Farrell DL; Dougan K; Kobayashi B
    J Am Board Fam Pract; 1996; 9(1):53-5. PubMed ID: 8770810
    [No Abstract]   [Full Text] [Related]  

  • 16. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom.
    Miller E; Andrews N; Stowe J; Grant A; Waight P; Taylor B
    Am J Epidemiol; 2007 Mar; 165(6):704-9. PubMed ID: 17204517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine-associated thrombocytopenia.
    Gan G; Liu H; Liang Z; Zhang G; Liu X; Ma L
    Thromb Res; 2022 Dec; 220():12-20. PubMed ID: 36265409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of measles-containing vaccines in 1-year-old children.
    Klein NP; Lewis E; Fireman B; Hambidge SJ; Naleway A; Nelson JC; Belongia EA; Yih WK; Nordin JD; Hechter RC; Weintraub E; Baxter R
    Pediatrics; 2015 Feb; 135(2):e321-9. PubMed ID: 25560438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.